Hardware Podcasts

Fraud in the Healthcare Industry & the Role of Whistleblowers

Global Medical Device Podcast · 12 Jan 2023 · 52m · Episode 299

What this episode covers

Jonathan Tycko, a founding partner at Tycko & Zavareei LLP, explains the False Claims Act and its application to the medical device industry, highlighting how fraud on the FDA, anti-kickback violations, and improper billing can lead to massive penalties. He details the whistleblower process, noting that the government intervenes in about 20% of cases but wins most of them, and discusses the financial rewards for relators. Tycko advises companies to foster internal compliance cultures to prevent employees from going to the government, emphasizing that individual executives can face criminal charges for intentional fraud.

Most relevant to

large enterprises

Topics

Mentioned

Companies
Tycko & Zavareei LLP, Green Light Guru
Also
The Garrulous Gavel, False Claims Act, Department of Justice, FDA, Medicare, VA

Related episodes from other shows

Other shows on the same ground, closest first.

  • Let's Combinate · 33m

    115 - Bottle of Lies, Generic Drugs Quality, Ranbaxy, Audits, and Inspiring Quality Pros with NYT Best-Selling Author, Katherine Eban

    Katherine Eban, author of the New York Times bestseller 'Bottle of Lies', discusses her decade-long investigation into quality failures in the generic drug industry, focusing on the fraudulent practices of Indian manufacturer Ranbaxy. She details how Ranbaxy manipulated and fabricated data to secure regulatory approvals, creating a 'dual-track' system where lower-quality drugs were sent to less regulated markets while better-tested versions went to the US and Europe. Eban highlights the role of whistleblower Dinesh Takur and FDA inspector Peter Baker in uncovering these systemic issues, while also critiquing the FDA's reliance on pre-announced inspections and the ethical culture of pharmaceutical companies.

    Quality & yieldCertification & compliance
    6 chapters

  • Let's Combinate · 33m

    056 - "Non-Promotional Compliance" with Darshan Kulkarni

    Darshan Kulkarni, an FDA regulatory lawyer and host of DarshanTalks, explains the legal distinction between promotional and non-promotional speech in the pharmaceutical industry, focusing on the First Amendment protections for scientific discussion. He details how the FDA's attempt to control off-label promotion by medical affairs was challenged in the Washington Legal Foundation case, leading to a 'quiet truce' where companies maintain strict separation between commercial and scientific roles to avoid multi-billion dollar False Claims Act fines. Kulkarni also discusses the operational challenges of the Sunshine Act, noting how mandatory sharing of journal articles can inadvertently register as transfers of value, creating friction with healthcare professionals.

    Policy, trade & tariffsMarketing & brand
    6 chapters

  • Let's Combinate · 1h 00m

    047 - "Truthful Not Misleading" with Darshan Kulkarni

    Darshan Kulkarni, an FDA regulatory attorney and Adjunct Law Professor at Drexel University, explains the distinction between regulatory and legal compliance in the life sciences industry. He details how the First Amendment influences US promotional compliance, particularly regarding off-label speech and the 'truthful not misleading' standard established by recent court cases. Kulkarni also discusses the operational differences between FDA divisions for drugs (OPDP) and devices (CDRH), noting the latter's limited enforcement resources, and highlights the implications of the Sunshine Act on physician interactions.

    Certification & complianceIntellectual property
    9 chapters

  • Let's Combinate · 34m

    201 - Inside a $300M FDA Remediation, Lessons from Zimmer to EpiPen Warning Letters, 99.999% Reliability and Quality 4.0

    Jeff Gensler, a veteran quality executive, details his experience leading massive FDA remediation efforts at Zimmer Biomet and Pfizer’s Meridian Medical Technologies. He explains how his team managed a $300M remediation of 1,400 Design History Files (DHFs) at Zimmer and achieved 99.999% reliability for the EpiPen through rigorous CAPA processes and FDA negotiations. Gensler also discusses his transition to Kindeva Drug Delivery, where he oversaw a state-of-the-art facility buildout, and his current work founding the Quality 4.0 Consortium to help small and mid-sized pharma companies adopt digital quality systems like Electronic Batch Records (EBRs) and AI.

    Quality & yieldCertification & compliance
    6 chapters

  • Let's Combinate · 39m

    087 - From Crime Reporting to Regulatory Affairs and On/Off The Record with Ferdous Al-Faruque

    Ferdous Al-Faruque, known as Danny, Senior Editor at RAPS, discusses his transition from crime reporting to covering medical device and pharma regulations, including his work on FDA user fee negotiations and digital health. He explains the journalistic rules of engagement, detailing the distinctions between off-the-record, on-background, and on-deep-background conversations to protect sources while maintaining credibility. Al-Faruque also outlines his editorial process at RAPS, emphasizing the importance of independent reporting, ethical standards, and the operational challenges of covering complex regulatory trends like gene therapy and digital health with limited resources.

    Medical & health devicesIntellectual property
    7 chapters

The summary, chapters and topics are generated from the episode’s audio by this directory, not written by Global Medical Device Podcast. The episode itself belongs to its publisher.